PLEASE FIND BELOW THE 2018 FALL CONFERENCE AGENDA
Tuesday, October 16, 2018
8:00 AM - 8:30 AM
Registration, welcome coffee and networking
8:30 AM - 8:40 AM
Chairman's Opening Address
Eldora Ellison, Partner, Sterne Kessler
8:40 AM - 9:10 AM
Keynote Address: US Patent Enforceability Outlook 
Eldora Ellison, Partner, Sterne Kessler
9:10 AM - 9:30 AM

Patent Rights in Canada - an update on recent developments

  • New linkage regime for pharmaceuticals/biologics -  for better or worse
  • Securing supplementary protection in Canada
  • Regulatory changes to pricing of patented medicines
Yoon Kang, Partner, Smart & Biggar
Daphne Lainson, Partner, Smart & Biggar
9:30 AM - 10:00 AM

Panel Discussion: How do we Ensure Effective Protection for Antibodies?

Moderator:
Brian Gummow, Counsel, Hailey & Guiliano

Panellists: 
Glyn Truscott, Partner - UK & European Patent Attorney, Elkington & Fife
Atabak Royaee, Associate Director & Senior Counsel, Boehringer Ingelheim Pharmaceuticals
Stephanie Yonker, Vice President of Legal, Alector
Kathy Coulter, Senior IP Counsel, Bristol-Myers Squibb

10:00 AM - 10:30 AM
Panel Discussion: IP Considerations in Personalised Medicine
 
Moderator:
Filko Prugo, Partner & Chair, Life Sciences IP Litigation, Ropes & Gray

Panellists:
Jason Christiansen, Senior Director, Assistant General Counsel, IP, Adamas Pharmaceuticals
John Sninsky, Chief Scientific Officer, CareDx
Aruna Gambhir, Chief Executive Officer, CellSight Technologies
10:30 AM - 10:50 AM
Evidence Collection Procedure and Protection of Confidential Information in Patent Litigation in Japan
  • The rise of unbranded generics: What does the future hold?
  • Patent Prosecution Practice in Asia: Jurisdictional Overview
  • Counterfeiting challenges: How can brand owners protect their rights and are global enforcement efforts yielding results?
Takanori Abe, Founder & Attorney, Abe & Partners
10:50 AM - 11:20 AM
Morning coffee and networking 
11:20 AM - 12:00 PM
Panel Discussion: Focus on Mergers & Acquisitions
  • What’s driving the current high level of M&A?
  • What impact is US tax reform having on M&A activity?
  • Are acquisitions a replacement for innovation – and what’s the impact of that?
  • What should be the key IP Considerations in M&A?
Moderator: 
Peter Scott, Publisher, LSIPR
Panellists: 
Tracy MacNeal, President, XimedicaDx
Rebecca Lin, VP of Strategy and Global Business Development, Potrero Medical
Joel Harris, Senior Director of IP, Incube Labs
12:00 PM - 12:15 PM
Don’t Rock the Boat, Change is a Frightening Proposition
Mitchell Atherton, Global Strategy Director, SHIP Global IP
12:15 PM - 12:45 PM

The Intersection of High-Tech and Life Sciences Patent Law: When Worlds Collide

Nathan Zhang, Counsel, Global Litigation and Investigations, Applied Materials

12:45 PM - 1:15 PM
Talking Heads: Updates and Developments in Europe
  • Supplementary Protection Certificates Overview
  • What’s the latest on the Unified Patent Court?
  • Examining Plausibility
Host:
Peter Scott, Publisher, LSIPR
 
Talking Heads:
Joel Coles, Senior Associate, Powell Gilbert
Bethan Hopewell, Partner, Powell Gilbert
1:15 PM - 2:00 PM
Lunch and networking
2:00 PM - 2:10 PM
Roundtable Discussion Groups 
 
Taking part in these discussions offers delegates and speakers the opportunity to focus on topics of specific interest, within a small group. 40-45 minutes is set aside for each rotation – and delegates may choose two discussion tables. The roundtable discussion groups give delegates even more opportunity to share knowledge and opinion, and ends with a moderator round-up of key findings, providing delegates with an insight into all eight topics.
 
SESSION 1 - PLEASE CHOOSE YOUR FIRST TABLE FROM THE FOLLOWING:
2:10 PM - 2:50 PM
Considerations When Drafting CRISPR Patent Applications

Patrick Morris, Partner, Perkins Coie
How do we Ensure Effective Protection of Antibodies?
 
Yifan Mao, Associate, Kilpatrick Townsend & Stockton
Impact of IPR and PGR Proceedings on Biologics and Biosimilars
 
Brian Gummow, Counsel, Hailey & Guiliano
IP Considerations in Personalised Medicine 
 
Jason Christiansen, Senior Director, Assistant General Counsel, Intellectual Property, Adamas Pharmaceuticals
 
Licensing and Joint Ownership of IP: Practical Strategies
 
Raymond Doss, Senior Counsel, Amgen
Life Sciences Patents Open Table: Solving  In-House Counsel Challenges
 
BrianSlater, Partner & Chair of Life Sciences, Kramer Levin
Second Medical Use Opportunities from Personalised Healthcare Inventions in Europe
 
Laurence Gainey, Patent Director, HGF
Strategies in Second Medical Use Cases
 
Filko Prugo, Partner, Ropes & Gray
Charlotte Jacobsen, Partner, Ropes & Gray
2:50 PM - 2:55 PM
SESSION 2 - PLEASE CHOOSE YOUR SECOND TABLE FROM THE FOLLOWING: 
2:55 PM - 3:40 PM
Considerations When Drafting CRISPR Patent Applications
 
Patrick Morris, Partner, Perkins Coie
How do we Ensure Effective Protection of Antibodies?
 
Yifan Mao, Associate, Kilpatrick Townsend & Stockton
Impact of IPR and PGR Proceedings on Biologics and Biosimilars
 
Brian Gummow, Counsel, Hailey & Guiliano
Licensing and Joint Ownership of IP: Practical Strategies
 
Raymond Doss, Senior Counsel, Amgen
Life Sciences Patents Open Table: Solving In-House Counsel Challenges
 
BrianSlater, Partner & Chair of Life Sciences , Kramer Levin
Strategies in Second Medical Use Cases
 
Filko Prugo, Partner, Ropes & Gray
Charlotte Jacobsen, Partner, Ropes & Gray

Second Medical Use Opportunities from Personalised Healthcare Inventions in Europe

Laurence Gainey, Patent Director, HGF

IP Considerations in Personalised Medicine
 
Jason Christiansen, Senior Director, Assistant General Counsel, Intellectual Property, Adamas Pharmaceuticals
3:40 PM - 4:00 PM
Discussion group round-up: Key findings and points of note
4:00 PM - 4:30 PM
Afternoon tea and networking 
4:30 PM - 4:55 PM
Course Selection and Navigation of Life Sciences Patents in Precision Medicine: a Stakeholder's Perspective
 
  • Diagnostic technology and content patents are critical elements of precision medicine
  • Recent patent law precedent has fundamentally changed patent strategies and claims
  • Pragmatic consideration of sea changes in patent law inform biomarker commercialization
  • Plans for capitalization and enforcement inform patent strategy
John Sninsky, Chief Scientific Officer, CareDx
4:55 PM - 5:20 PM
Recent Advances in Artificial Intelligence in Healthcare
 
John Axerio-Cilies, COO & Founder, Arterys
5:20 PM - 6:00 PM
Panel Discussion: In-house Counsel Share Day-to-Day Challenges in Securing and Protecting Patents
 
Moderator:
Eldora Ellison, Partner, Sterne Kessler
 
Panellists:
Nada Rastad, General Counsel, 3Scan
Robert Bernstein, Intellectual Property Attorney, Plexxikon
Aly Fuller, VP, Intellectual Property, Prolacta Bioscience
Raymond Doss, Senior Counsel, Amgen
6:00 PM - 7:00 PM
Chair’s Closing Remarks 
 
Eldora Ellison, Partner, Sterne Kessler
 
Followed by Networking Drinks Reception

Contact our team

For sponsoring: 
Kirsty Pocock
Commercial Director
+44 (0) 203 301 8211
 
 
For speaking: 
Sarah Gooding 
Head of Content
sgooding@newtonmedia.co.uk
+44 (0) 7957672202
For attending: 
Andrew Boughton
Delegate Liaison
+44 (0) 203 301 8236